08:56:19 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CYCC - CYCLACEL PHARMACEUTICALS INC - http://www.cyclacel.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYCC - Q1.51.70·2.891.21.78-0.08-4.310.318521.89  1.95  1.771713.1934  1.5219:49:34Apr 0115 min RT 2¢

Recent Trades - Last 10 of 52
Time ETExPriceChangeVolume
19:49:34Q1.75-0.1015
19:49:34Q1.75-0.1050
16:00:01Q1.79-0.0614
16:00:01Q1.79-0.063
16:00:01Q1.79-0.061
15:59:53Q1.78-0.08100
15:59:53Q1.78-0.0723
15:59:52Q1.79-0.0628
15:58:14Q1.80-0.0520
15:19:19Q1.8079-0.042111

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-01 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
2024-03-19 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-03-13 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
2024-03-07 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-06 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
2024-02-20 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
2024-01-30 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
2024-01-08 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
2024-01-02 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Present at Biotech Showcase 2024
2023-12-22 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
2023-12-18 09:00U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
2023-12-12 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Reverse Stock Split
2023-11-30 09:15U:CYCCNews ReleaseCyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
2023-11-28 17:15U:CYCCNews ReleaseCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
2023-11-13 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
2023-11-07 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
2023-08-09 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
2023-08-03 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
2023-05-11 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
2023-05-04 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results